Skip to main content
Erschienen in: Digestive Diseases and Sciences 11/2009

01.11.2009 | Review

Potential Anti-inflammatory Effects of Proton Pump Inhibitors: A Review and Discussion of the Clinical Implications

verfasst von: Ramalinga R. Kedika, Rhonda F. Souza, Stuart Jon Spechler

Erschienen in: Digestive Diseases and Sciences | Ausgabe 11/2009

Einloggen, um Zugang zu erhalten

Abstract

Proton pump inhibitors (PPIs) are potent blockers of gastric acid secretion, and are widely regarded as the agents of choice for the treatment of acid-peptic disorders. For patients with upper gastrointestinal symptoms of uncertain etiology, improvement with PPI therapy is considered prima facie evidence of a pathogenetic role for acid-peptic disease. In addition to anti-secretory effects, however, PPIs have been found to have anti-oxidant properties and direct effects on neutrophils, monocytes, endothelial, and epithelial cells that might prevent inflammation. Those anti-inflammatory effects of the PPIs might influence a variety of inflammatory disorders, both peptic and non-peptic, within and outside of the gastrointestinal tract. The purpose of this report is to review the mechanisms whereby PPIs might exert anti-inflammatory effects exclusive of gastric acid inhibition, to discuss the clinical implications of those effects, and to emphasize that a clinical response to PPIs should not be construed as proof for an underlying acid-peptic disorder.
Literatur
1.
Zurück zum Zitat Shin JM, Sachs G. Pharmacology of proton pump inhibitors. Curr Gastroenterol Rep. 2008;10:528–534.CrossRefPubMed Shin JM, Sachs G. Pharmacology of proton pump inhibitors. Curr Gastroenterol Rep. 2008;10:528–534.CrossRefPubMed
2.
3.
Zurück zum Zitat Lassen A, Hallas J, Schaffalitzky De Muckadell OB. Use of anti-secretory medication: a population-based cohort study. Aliment Pharmacol Ther. 2004;20:577–583.CrossRefPubMed Lassen A, Hallas J, Schaffalitzky De Muckadell OB. Use of anti-secretory medication: a population-based cohort study. Aliment Pharmacol Ther. 2004;20:577–583.CrossRefPubMed
4.
Zurück zum Zitat Ichikawa H, Yoshida N, Takagi T, et al. Lansoprazole ameliorates intestinal mucosal damage induced by ischemia-reperfusion in rats. World J Gastroenterol. 2004;10:2814–2817.PubMed Ichikawa H, Yoshida N, Takagi T, et al. Lansoprazole ameliorates intestinal mucosal damage induced by ischemia-reperfusion in rats. World J Gastroenterol. 2004;10:2814–2817.PubMed
5.
Zurück zum Zitat Kuroda M, Yoshida N, Ichikawa H, et al. Lansoprazole, a proton pump inhibitor, reduces the severity of indomethacin-induced rat enteritis. Int J Mol Med. 2006;17:89–93.PubMed Kuroda M, Yoshida N, Ichikawa H, et al. Lansoprazole, a proton pump inhibitor, reduces the severity of indomethacin-induced rat enteritis. Int J Mol Med. 2006;17:89–93.PubMed
6.
7.
Zurück zum Zitat Namazi MR, Jowkar F. A succinct review of the general and immunological pharmacologic effects of proton pump inhibitors. J Clin Pharm Ther. 2008;33:215–217.CrossRefPubMed Namazi MR, Jowkar F. A succinct review of the general and immunological pharmacologic effects of proton pump inhibitors. J Clin Pharm Ther. 2008;33:215–217.CrossRefPubMed
8.
Zurück zum Zitat Weiss SJ. Oxygen, ischemia and inflammation. Acta Physiol Scand Suppl. 1986;548:9–37.PubMed Weiss SJ. Oxygen, ischemia and inflammation. Acta Physiol Scand Suppl. 1986;548:9–37.PubMed
9.
Zurück zum Zitat Lapenna D, de Gioia S, Ciofani G, Festi D, Cuccurullo F. Antioxidant properties of omeprazole. FEBS Lett. 1996;382:189–192.CrossRefPubMed Lapenna D, de Gioia S, Ciofani G, Festi D, Cuccurullo F. Antioxidant properties of omeprazole. FEBS Lett. 1996;382:189–192.CrossRefPubMed
10.
Zurück zum Zitat Li XQ, Andersson TB, Ahlström M, Weidolf L. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. Drug Metab Dispos. 2004;32:821–827.CrossRefPubMed Li XQ, Andersson TB, Ahlström M, Weidolf L. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. Drug Metab Dispos. 2004;32:821–827.CrossRefPubMed
11.
Zurück zum Zitat Cederberg C, Thomson AB, Mahachai V, et al. Effect of intravenous and oral omeprazole on 24-hour intragastric acidity in duodenal ulcer patients. Gastroenterology. 1992;103:913–918.PubMed Cederberg C, Thomson AB, Mahachai V, et al. Effect of intravenous and oral omeprazole on 24-hour intragastric acidity in duodenal ulcer patients. Gastroenterology. 1992;103:913–918.PubMed
12.
Zurück zum Zitat Blandizzi C, Fornai M, Colucci R, et al. Lansoprazole prevents experimental gastric injury induced by non-steroidal anti-inflammatory drugs through a reduction of mucosal oxidative damage. World J Gastroenterol. 2005;11:4052–4060.PubMed Blandizzi C, Fornai M, Colucci R, et al. Lansoprazole prevents experimental gastric injury induced by non-steroidal anti-inflammatory drugs through a reduction of mucosal oxidative damage. World J Gastroenterol. 2005;11:4052–4060.PubMed
13.
Zurück zum Zitat Simon WA, Sturm E, Hartmann HJ, Weser U. Hydroxyl radical scavenging reactivity of proton pump inhibitors. Biochem Pharmacol. 2006;71:1337–1341.CrossRefPubMed Simon WA, Sturm E, Hartmann HJ, Weser U. Hydroxyl radical scavenging reactivity of proton pump inhibitors. Biochem Pharmacol. 2006;71:1337–1341.CrossRefPubMed
14.
Zurück zum Zitat Biswas K, Bandyopadhyay U, Chattopadhyay I, Varadaraj A, Ali E, Banerjee RK. A novel antioxidant and antiapoptotic role of omeprazole to block gastric ulcer through scavenging of hydroxyl radical. J Biol Chem. 2003;278:10993–11001.CrossRefPubMed Biswas K, Bandyopadhyay U, Chattopadhyay I, Varadaraj A, Ali E, Banerjee RK. A novel antioxidant and antiapoptotic role of omeprazole to block gastric ulcer through scavenging of hydroxyl radical. J Biol Chem. 2003;278:10993–11001.CrossRefPubMed
15.
Zurück zum Zitat Pastoris O, Verri M, Boschi F, et al. Effects of esomeprazole on glutathione levels and mitochondrial oxidative phosphorylation in the gastric mucosa of rats treated with indomethacin. Naunyn Schmiedebergs Arch Pharmacol. 2008;378:421–429.CrossRefPubMed Pastoris O, Verri M, Boschi F, et al. Effects of esomeprazole on glutathione levels and mitochondrial oxidative phosphorylation in the gastric mucosa of rats treated with indomethacin. Naunyn Schmiedebergs Arch Pharmacol. 2008;378:421–429.CrossRefPubMed
16.
Zurück zum Zitat Blandizzi C, Natale G, Gherardi G, et al. Acid-independent gastroprotective effects of lansoprazole in experimental mucosal injury. Dig Dis Sci. 1999;44:2039–2050.CrossRefPubMed Blandizzi C, Natale G, Gherardi G, et al. Acid-independent gastroprotective effects of lansoprazole in experimental mucosal injury. Dig Dis Sci. 1999;44:2039–2050.CrossRefPubMed
17.
Zurück zum Zitat Koch TR, Petro A, Darrabie M, Opara EC. Effect of the H, K-ATPase inhibitor, esomeprazole magnesium, on gut total antioxidant capacity in mice. J Nutr Biochem. 2004;15:522–526.CrossRefPubMed Koch TR, Petro A, Darrabie M, Opara EC. Effect of the H, K-ATPase inhibitor, esomeprazole magnesium, on gut total antioxidant capacity in mice. J Nutr Biochem. 2004;15:522–526.CrossRefPubMed
18.
Zurück zum Zitat Becker JC, Grosser N, Waltke C, et al. Beyond gastric acid reduction: proton pump inhibitors induce heme oxygenase-1 in gastric and endothelial cells. Biochem Biophys Res Commun. 2006;345:1014–1021.CrossRefPubMed Becker JC, Grosser N, Waltke C, et al. Beyond gastric acid reduction: proton pump inhibitors induce heme oxygenase-1 in gastric and endothelial cells. Biochem Biophys Res Commun. 2006;345:1014–1021.CrossRefPubMed
19.
Zurück zum Zitat Ritter M, Schratzberger P, Rossmann H, et al. Effect of inhibitors of Na+/H+-exchange and gastric H+/K+ ATPase on cell volume, intracellular pH and migration of human polymorphonuclear leucocytes. Br J Pharmacol. 1998;124:627–638.CrossRefPubMed Ritter M, Schratzberger P, Rossmann H, et al. Effect of inhibitors of Na+/H+-exchange and gastric H+/K+ ATPase on cell volume, intracellular pH and migration of human polymorphonuclear leucocytes. Br J Pharmacol. 1998;124:627–638.CrossRefPubMed
20.
Zurück zum Zitat Lafourcade C, Sobo K, Kieffer-Jaquinod S, Garin J, van der Goot FG. Regulation of the V-ATPase along the endocytic pathway occurs through reversible subunit association and membrane localization. PLoS ONE. 2008;3(7):e2758.CrossRefPubMed Lafourcade C, Sobo K, Kieffer-Jaquinod S, Garin J, van der Goot FG. Regulation of the V-ATPase along the endocytic pathway occurs through reversible subunit association and membrane localization. PLoS ONE. 2008;3(7):e2758.CrossRefPubMed
21.
Zurück zum Zitat Harada M, Shakado S, Sakisaka S, et al. Bafilomycin A1, a specific inhibitor of V-type H+-ATPases, inhibits the acidification of endocytic structures and inhibits horseradish peroxidase uptake in isolated rat sinusoidal endothelial cells. Liver. 1997;17:244–250.PubMed Harada M, Shakado S, Sakisaka S, et al. Bafilomycin A1, a specific inhibitor of V-type H+-ATPases, inhibits the acidification of endocytic structures and inhibits horseradish peroxidase uptake in isolated rat sinusoidal endothelial cells. Liver. 1997;17:244–250.PubMed
22.
Zurück zum Zitat Luciani F, Spada M, De Milito A, et al. Effect of proton pump inhibitor pretreatment on resistance of solid tumors to cytotoxic drugs. J Natl Cancer Inst. 2004;96:1702–1713.PubMed Luciani F, Spada M, De Milito A, et al. Effect of proton pump inhibitor pretreatment on resistance of solid tumors to cytotoxic drugs. J Natl Cancer Inst. 2004;96:1702–1713.PubMed
23.
Zurück zum Zitat Wandall JH. Effects of omeprazole on neutrophil chemotaxis, super oxide production, degranulation, and translocation of cytochrome b-245. Gut. 1992;33:617–621.CrossRefPubMed Wandall JH. Effects of omeprazole on neutrophil chemotaxis, super oxide production, degranulation, and translocation of cytochrome b-245. Gut. 1992;33:617–621.CrossRefPubMed
24.
Zurück zum Zitat Handa O, Yoshida N, Fujita N, et al. Molecular mechanisms involved in anti-inflammatory effects of proton pump inhibitors. Inflamm Res. 2006;55:476–480.CrossRefPubMed Handa O, Yoshida N, Fujita N, et al. Molecular mechanisms involved in anti-inflammatory effects of proton pump inhibitors. Inflamm Res. 2006;55:476–480.CrossRefPubMed
25.
Zurück zum Zitat Suzuki M, Nakamura M, Mori M, Miura S, Tsuchiya M, Ishil H. Lansoprazole inhibits oxygen-derived free radical production from neutrophils activated by Helicobacter pylori. J Clin Gastroenterol. 1995;20(Suppl 2):S93–S96.PubMedCrossRef Suzuki M, Nakamura M, Mori M, Miura S, Tsuchiya M, Ishil H. Lansoprazole inhibits oxygen-derived free radical production from neutrophils activated by Helicobacter pylori. J Clin Gastroenterol. 1995;20(Suppl 2):S93–S96.PubMedCrossRef
26.
Zurück zum Zitat Styrt B, Klempner MS. Inhibition of neutrophil oxidative metabolism by lysosomotropic weak bases. Blood. 1986;67:334–342.PubMed Styrt B, Klempner MS. Inhibition of neutrophil oxidative metabolism by lysosomotropic weak bases. Blood. 1986;67:334–342.PubMed
27.
Zurück zum Zitat Suzuki M, Mori M, Miura S, et al. Omeprazole attenuates oxygen-derived free radical production from human neutrophils. Free Radic Biol Med. 1996;21:727–731.CrossRefPubMed Suzuki M, Mori M, Miura S, et al. Omeprazole attenuates oxygen-derived free radical production from human neutrophils. Free Radic Biol Med. 1996;21:727–731.CrossRefPubMed
28.
Zurück zum Zitat Agastya G, West BC, Callahan JM. Omeprazole inhibits phagocytosis and acidification of phagolysosomes of normal human neutrophils in vitro. Immunopharmacol Immunotoxicol. 2000;22:357–372.CrossRefPubMed Agastya G, West BC, Callahan JM. Omeprazole inhibits phagocytosis and acidification of phagolysosomes of normal human neutrophils in vitro. Immunopharmacol Immunotoxicol. 2000;22:357–372.CrossRefPubMed
29.
Zurück zum Zitat Zedtwitz-Liebenstein K, Wenisch C, Patruta S, Parschalk B, Daxböck F, Graninger W. Omeprazole treatment diminishes intra- and extracellular neutrophil reactive oxygen production and bactericidal activity. Crit Care Med. 2002;30:1118–1122.CrossRefPubMed Zedtwitz-Liebenstein K, Wenisch C, Patruta S, Parschalk B, Daxböck F, Graninger W. Omeprazole treatment diminishes intra- and extracellular neutrophil reactive oxygen production and bactericidal activity. Crit Care Med. 2002;30:1118–1122.CrossRefPubMed
30.
Zurück zum Zitat Yoshida N, Yoshikawa T, Tanaka Y, et al. A new mechanism for anti-inflammatory actions of proton pump inhibitors—inhibitory effects on neutrophil-endothelial cell interactions. Aliment Pharmacol Ther. 2000;14(Suppl 1):74–81.CrossRefPubMed Yoshida N, Yoshikawa T, Tanaka Y, et al. A new mechanism for anti-inflammatory actions of proton pump inhibitors—inhibitory effects on neutrophil-endothelial cell interactions. Aliment Pharmacol Ther. 2000;14(Suppl 1):74–81.CrossRefPubMed
31.
Zurück zum Zitat Sasaki T, Yamaya M, Yasuda H, et al. The proton pump inhibitor lansoprazole inhibits rhinovirus infection in cultured human tracheal epithelial cells. Eur J Pharmacol. 2005;509(2–3):201–210.CrossRefPubMed Sasaki T, Yamaya M, Yasuda H, et al. The proton pump inhibitor lansoprazole inhibits rhinovirus infection in cultured human tracheal epithelial cells. Eur J Pharmacol. 2005;509(2–3):201–210.CrossRefPubMed
32.
Zurück zum Zitat Ohara T, Arakawa T. Lansoprazole decreases peripheral blood monocytes and intercellular adhesion molecule-1-positive mononuclear cells. Dig Dis Sci. 1999;44:1710–1715.CrossRefPubMed Ohara T, Arakawa T. Lansoprazole decreases peripheral blood monocytes and intercellular adhesion molecule-1-positive mononuclear cells. Dig Dis Sci. 1999;44:1710–1715.CrossRefPubMed
33.
Zurück zum Zitat Martins de Oliveira R, Antunes E, Pedrazzoli J Jr, Gambero A. The inhibitory effects of H+ K+ ATPase inhibitors on human neutrophils in vitro: restoration by a K+ ionophore. Inflamm Res. 2007;56:105–111.CrossRefPubMed Martins de Oliveira R, Antunes E, Pedrazzoli J Jr, Gambero A. The inhibitory effects of H+ K+ ATPase inhibitors on human neutrophils in vitro: restoration by a K+ ionophore. Inflamm Res. 2007;56:105–111.CrossRefPubMed
34.
Zurück zum Zitat Smith WB, Gamble JR, Clark-Lewis I, Vadas MA. Interleukin-8 induces neutrophil transendothelial migration. Immunology. 1991;72:65–72.PubMed Smith WB, Gamble JR, Clark-Lewis I, Vadas MA. Interleukin-8 induces neutrophil transendothelial migration. Immunology. 1991;72:65–72.PubMed
35.
36.
Zurück zum Zitat Verdu E, Viani F, Armstrong D, et al. Effect of omeprazole on intragastric bacterial counts, nitrates, nitrites, and N-nitroso compounds. Gut. 1994;35:455–460.CrossRefPubMed Verdu E, Viani F, Armstrong D, et al. Effect of omeprazole on intragastric bacterial counts, nitrates, nitrites, and N-nitroso compounds. Gut. 1994;35:455–460.CrossRefPubMed
37.
Zurück zum Zitat Vesper BJ, Jawdi A, Altman KW, Haines GKIII, Tao L, Radosevich JA. The effect of proton pump inhibitors on the human microbiota. Curr Drug Metab. 2009;10:84–89.CrossRefPubMed Vesper BJ, Jawdi A, Altman KW, Haines GKIII, Tao L, Radosevich JA. The effect of proton pump inhibitors on the human microbiota. Curr Drug Metab. 2009;10:84–89.CrossRefPubMed
38.
Zurück zum Zitat Nakao M, Malfertheiner P. Growth inhibitory and bactericidal activities of lansoprazole compared with those of omeprazole and pantoprazole against Helicobacter pylori. Helicobacter. 1998;3:21–27.CrossRefPubMed Nakao M, Malfertheiner P. Growth inhibitory and bactericidal activities of lansoprazole compared with those of omeprazole and pantoprazole against Helicobacter pylori. Helicobacter. 1998;3:21–27.CrossRefPubMed
39.
Zurück zum Zitat Monk BC, Mason AB, Abramochkin G, Haber JE, Seto-Young D, Perlin DS. The yeast plasma membrane proton pumping ATPase is a viable antifungal target. I. Effects of the cysteine-modifying reagent omeprazole. Biochim Biophys Acta. 1995;1239:81–90.CrossRefPubMed Monk BC, Mason AB, Abramochkin G, Haber JE, Seto-Young D, Perlin DS. The yeast plasma membrane proton pumping ATPase is a viable antifungal target. I. Effects of the cysteine-modifying reagent omeprazole. Biochim Biophys Acta. 1995;1239:81–90.CrossRefPubMed
40.
Zurück zum Zitat Furuta GT, Liacouras CA, Collins MH, Gupta SK, Justinich C, Putnam PE, Bonis P, Hassall E, Straumann A, Rothenberg ME, First International Gastrointestinal Eosinophil Research Symposium (FIGERS) Subcommittees. Eosinophilic esophagitis in children and adults: a systematic review and consensus recommendations for diagnosis and treatment. Gastroenterology. 2007;133:1342–1363. Furuta GT, Liacouras CA, Collins MH, Gupta SK, Justinich C, Putnam PE, Bonis P, Hassall E, Straumann A, Rothenberg ME, First International Gastrointestinal Eosinophil Research Symposium (FIGERS) Subcommittees. Eosinophilic esophagitis in children and adults: a systematic review and consensus recommendations for diagnosis and treatment. Gastroenterology. 2007;133:1342–1363.
41.
Zurück zum Zitat Spechler SJ, Genta RM, Souza RF. Thoughts on the complex relationship between gastroesophageal reflux disease and eosinophilic esophagitis. Am J Gastroenterol. 2007;102:1301–1306.CrossRefPubMed Spechler SJ, Genta RM, Souza RF. Thoughts on the complex relationship between gastroesophageal reflux disease and eosinophilic esophagitis. Am J Gastroenterol. 2007;102:1301–1306.CrossRefPubMed
42.
Zurück zum Zitat Ngo P, Furuta GT, Antonioli DA, Fox VL. Eosinophils in the esophagus—peptic or allergic eosinophilic esophagitis? Case series of three patients with esophageal eosinophilia. Am J Gastroenterol. 2006;101:1666–1670.CrossRefPubMed Ngo P, Furuta GT, Antonioli DA, Fox VL. Eosinophils in the esophagus—peptic or allergic eosinophilic esophagitis? Case series of three patients with esophageal eosinophilia. Am J Gastroenterol. 2006;101:1666–1670.CrossRefPubMed
43.
Zurück zum Zitat Aceves SS, Furuta GT, Spechler SJ. Integrated approach to treatment of children and adults with eosinophilic esophagitis. Gastrointest Endosc Clin N Am. 2008;18:195–217.CrossRefPubMed Aceves SS, Furuta GT, Spechler SJ. Integrated approach to treatment of children and adults with eosinophilic esophagitis. Gastrointest Endosc Clin N Am. 2008;18:195–217.CrossRefPubMed
44.
Zurück zum Zitat Bohm M, Richter JE. Treatment of eosinophilic esophagitis: overview, current limitations, and future direction. Am J Gastroenterol. 2008;103:2635–2644.CrossRefPubMed Bohm M, Richter JE. Treatment of eosinophilic esophagitis: overview, current limitations, and future direction. Am J Gastroenterol. 2008;103:2635–2644.CrossRefPubMed
45.
Zurück zum Zitat Rafiee P, Theriot ME, Nelson VM, et al. Human esophageal microvascular endothelial cells respond to acidic pH stress by PI3K/AKT and p38 MAPK-regulated induction of Hsp70 and Hsp27. Am J Physiol Cell Physiol. 2006;291:C931–C945.CrossRefPubMed Rafiee P, Theriot ME, Nelson VM, et al. Human esophageal microvascular endothelial cells respond to acidic pH stress by PI3K/AKT and p38 MAPK-regulated induction of Hsp70 and Hsp27. Am J Physiol Cell Physiol. 2006;291:C931–C945.CrossRefPubMed
46.
Zurück zum Zitat Barthel SR, Annis DS, Mosher DF, Johansson MW. Differential engagement of modules 1 and 4 of vascular cell adhesion molecule-1 (CD106) by integrins alpha4beta1 (CD49d/29) and alphaMbeta2 (CD11b/18) of eosinophils. J Biol Chem. 2006;281:32175–32187.CrossRefPubMed Barthel SR, Annis DS, Mosher DF, Johansson MW. Differential engagement of modules 1 and 4 of vascular cell adhesion molecule-1 (CD106) by integrins alpha4beta1 (CD49d/29) and alphaMbeta2 (CD11b/18) of eosinophils. J Biol Chem. 2006;281:32175–32187.CrossRefPubMed
47.
Zurück zum Zitat Laheij RJ, Sturkenboom MC, Hassing RJ, Dieleman J, Stricker BH, Jansen JB. Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs. JAMA. 2004;292:1955–1960.CrossRefPubMed Laheij RJ, Sturkenboom MC, Hassing RJ, Dieleman J, Stricker BH, Jansen JB. Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs. JAMA. 2004;292:1955–1960.CrossRefPubMed
48.
Zurück zum Zitat Herzig SJ, Howell MD, Ngo LH, Marcantonio ER. Acid-suppressive medication use and the risk for hospital-acquired pneumonia. JAMA. 2009;301:2120–2128.CrossRefPubMed Herzig SJ, Howell MD, Ngo LH, Marcantonio ER. Acid-suppressive medication use and the risk for hospital-acquired pneumonia. JAMA. 2009;301:2120–2128.CrossRefPubMed
49.
Zurück zum Zitat Bajaj JS, Zadvornova Y, Heuman DM, et al. Association of proton pump inhibitor therapy with spontaneous bacterial peritonitis in cirrhotic patients with ascites. Am J Gastroenterol. 2009;104:1130–1134.CrossRefPubMed Bajaj JS, Zadvornova Y, Heuman DM, et al. Association of proton pump inhibitor therapy with spontaneous bacterial peritonitis in cirrhotic patients with ascites. Am J Gastroenterol. 2009;104:1130–1134.CrossRefPubMed
Metadaten
Titel
Potential Anti-inflammatory Effects of Proton Pump Inhibitors: A Review and Discussion of the Clinical Implications
verfasst von
Ramalinga R. Kedika
Rhonda F. Souza
Stuart Jon Spechler
Publikationsdatum
01.11.2009
Verlag
Springer US
Erschienen in
Digestive Diseases and Sciences / Ausgabe 11/2009
Print ISSN: 0163-2116
Elektronische ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-009-0951-9

Weitere Artikel der Ausgabe 11/2009

Digestive Diseases and Sciences 11/2009 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.